Journal of Visualized Experiments

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCI4) Exposure Through an Orogastric Tube --Manuscript Draft--

Article Type:	Invited Methods Article - Author Produced Video	
Manuscript Number:	JoVE60695R4	
Full Title:	Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube	
Section/Category:		
Keywords:	Acute liver injury (ALI); carbon tetrachloride (CCl4); hepatic injury; liver damage; rat model; Toxin	
Corresponding Author:	Matthew Bokyo, PhD Soroka Medical Center, Ben-Gurion University of the Negev Beer Sheva, Beer Sheva ISRAEL	
Corresponding Author's Institution:	Soroka Medical Center, Ben-Gurion University of the Negev	
Corresponding Author E-Mail:	matthewboykoresearch@gmail.com	
Order of Authors:	Dmitry Frank	
	Shiri Savir	
	Benjamin Fredrick Gruenbaum	
	Israel Melamed	
	Julia Grinshpun	
	Ruslan Kuts	
	Boris Knyazer	
	Alexander Zlotnik	
	Max Vinokur	
	Matthew Bokyo	
Additional Information:		
Question	Response	
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)	
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Beer Sheva, Israel	
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$1200)	

TITLE: Inducing Acute Liver Inju	ry in Rats via Carbon Tetrachloride (CCI4) Exposure Through an	1 2
Orogastric Tube		3
		4
AUTHORS AND AFFILIATIO		5
•	ir ^{1,*} , Benjamin F. Gruenbaum ² , Israel Melamed ³ , Julia Grinshpun ¹ ,	6
Rusidii Kuts , Doi is Kiiyazei	⁴ , Alexander Zlotnik ¹ , Max Vinokur ¹ , Matthew Boyko ¹	7 8
¹ Department of Anesthesic	ology and Critical Care, Soroka Medical Center, Ben-Gurion University	9
of the Negev, Beer-Sheva,	-	10
- '	ology, Yale University School of Medicine, New Haven, CT, USA	11
•	gery, Soroka University Medical Center and the Faculty of Health	12
•	ersity of the Negev, Beer-Sheva, Israel	13
	ology, Soroka University Medical Center and the Faculty of Health	14
Sciences, Ben-Gurion Unive	ersity of the Negev, Beer-Sheva, Israel	15
		16
*These authors contributed	d equally.	17
		18
Corresponding Author:		19
Matthew Boyko	(matthewboykoresearch@gmail.com)	20
		21
Email Addresses of Co-Aut		22
Dmitry Frank	(frdima16@gmail.com)	23
Shiri Savir	(yona.shiri@gmail.com)	24
Benjamin F. Gruenbaum	(bengruenbaum@gmail.com)	25
Israel Melamed	(melamedi@bgu.ac.il)	26
Ruslan Kuts	(ruslanKo@clalit.org.il)	27
Max Vinokur	(max.vinokur@gmail.com) (Knyazer@bgu.ac.il)	28 29
Boris Knyazer Julia Grinshpun	(inliag7648@gmail.com)	30
Alexander Zlotnik	(AleksZl@clalit.org.il)	31
AICAGITACT ZIOTITIK	(AICK32I@ClaiiC.Org.ii)	32
KEYWORDS:		33
	oon tetrachloride (CCl ₄), hepatic injury, liver damage, rat model, toxin	34
	,	35
SUMMARY:		36
This protocol describes a co	ommon and feasible method of inducing acute liver injury (ALI) via CCl ₄	37
exposure through an oroga	stric tube. CCl ₄ exposure induces ALI through the formation of reactive	38
oxygen species during its	biotransformation in the liver. This method is used to analyze the	39
pathophysiology of ALI and	l examine different hepatoprotective strategies.	40
		41
ABSTRACT:		42
	ays a crucial role in the development of hepatic failure, which is liver dysfunction including complications such as hepatic	43 44

encephalopathy and impaired protein synthesis. Appropriate animal models are vital to test the mechanism and pathophysiology of ALI and investigate different hepatoprotective strategies. Due to its ability to perform chemical transformations, carbon tetrachloride (CCl₄) is widely used in the liver to induce ALI through the formation of reactive oxygen species. CCl₄ exposure can be performed intraperitoneally, by inhalation, or through a nasogastric or orogastric tube. Here, we describe a rodent model, in which ALI is induced by CCl₄ exposure through an orogastric tube. This method is inexpensive, easily performed, and has minimal hazard risk. The model is highly reproducible and can be widely used to determine the efficacy of potential hepatoprotective strategies and assess markers of liver injury.

INTRODUCTION:

The frequency of toxic insults to the liver, especially due to alcohol and drug abuse, is increasing. Acute liver injury (ALI) is associated with high mortality rates and has caused clinical concerns^{1,2}. Toxic injury leads to death signaling pathways in the liver, resulting in hepatocyte apoptosis, necrosis, or pyroptosis. ALI plays a crucial role in the development of hepatic failure, which is characterized by severe liver dysfunction including complications such as hepatic encephalopathy and impaired protein synthesis^{3,4}. Although recent research has increased our knowledge about the physiological and pathological changes accompanying hepatic failure, it has not completely explained the pathomolecular features that affect the mechanisms of cell death. Furthermore, no medications are currently available to reverse the progressive deterioration in ALI patients. Currently, the only significantly effective treatment is liver transplantation^{5,6}.

In order to investigate the mechanism and pathophysiology of ALI and to test different hepatoprotective strategies, different animal models are used to induce ALI. A preferable animal model of ALI should mimic the pathological process of the disease via a reliable, validated, inexpensive and easy to apply method. Examples of experimental models include hepatotoxic agents, surgical procedures such as total or partial hepatectomy, complete or transient devascularization, and infective procedures⁷⁻⁹. Known hepatotoxic substances include galactosamine, acetaminophen, thioacetamide, azoxymethane and CCl₄. Of these, CCl₄ is widely used although it has not yet been well characterized¹⁰⁻¹³.

CCl₄ is an organic colorless liquid compound with a sweet smell and almost no flammability at lower temperatures. Exposure to high concentrations of CCl₄ can cause damage to the central nervous system, including deterioration of the liver and kidneys. CCl₄ induces ALI through its biotransformation in the liver, which forms reactive oxygen species. This occurs via the P450 cytochrome enzyme 2E1, forming an active metabolite and resulting in cell damage by macromolecule binding, enhancement of lipid peroxidation and disturbance of intracellular calcium homeostasis¹⁴. In addition, the CCl₄ model can be used to stimulate the astrocytes at the level of RNA synthesis¹⁵. This hepatotoxin has been administered by the intraperitoneal, intraportal, oral, and intragastric routes¹⁶.

In this protocol, we describe in detail CCl₄-induced ALI in rats via an orogastric tube. This method induces robust and reproducible ALI that can be used to investigate the pathogenesis of ALI. Determination of liver disease severity is monitored by measurement of serum glutamate-

pyruvate transaminase (GPT), glutamic oxaloacetic transaminase (GOT) enzymes and total	89
bilirubin (TB) as well as definitive histological diagnosis by hematoxylin and eosin (H&E) stained	90
liver tissues. Exposure to CCl ₄ through an intragastric access allows for a practical, inexpensive,	91
minimally invasive method with minimal hazard risk.	92
	93
PROTOCOL:	94
	95
The experiments were conducted according to the recommendations of the Declarations of	96
Helsinki and Tokyo and to the Guidelines for the Use of Experimental Animals of the European	97
Community. The experiments were approved by the Animal Care Committee of Ben-Gurion	98
University of the Negev.	99
NOTE: The CCL model has been generated and used in a previous study 17. The protocol timeline	100
NOTE: The CCl ₄ model has been generated and used in a previous study ¹⁷ . The protocol timeline is demonstrated in Table 1 .	101
is demonstrated in Table 1.	102 103
1. Preparing rats for the experimental procedure	103
1. Freparing rats for the experimental procedure	104
NOTE: Select adult male Sprague Dawley rats weighing 300–350 g.	105
TVO 12. Select dadit male spragae bawley rats weighing 500 550 g.	107
1.1. Obtain approval for experiments from Institutional Animal Care and Use Committee (IACUC).	108
(109
1.2. Maintain rats at room temperature (22 °C ± 1 °C), with 12 h light and 12 h dark cycles. Provide	110
rat chow and water ad libitum.	111
	112
1.3. Perform all experiments between 6:00 a.m. and 12:00 p.m.	113
	114
1.4. Shave the rat and disinfect the skin with alcohol.	115
	116
2. Determination of serum GOT, GPT, and TB baseline levels	117
	118
2.1. Anesthesia	119
	120
2.1.1. Prepare a continuous isoflurane administration system to induce anesthesia. Make sure	121
the vaporizer system is filled with isoflurane.	122
	123
2.1.2. Anesthetize the rat with 2% isoflurane. Confirm that the rat is fully anesthetized by	124
observing the movement and pedal reflex in response to external stimuli.	125
NOTE: Use 1–5% isoflurane for anesthesia induction and maintenance.	126
NOTE. Use 1–5% isolitifalle for allestifesia illuuction allu maintenalice.	127
2.2. Cannulate the tail vein with a 22 G catheter.	128 129
2.2. Carmanate the tail vent with a 22 G catheter.	130
2.3. Collect a 0.5 mL blood sample at baseline. Ensure that the blood volume retrieved does not	131
exceed IACUC guidelines.	132

	133
2.4. Perform blood biochemical analysis including the measurements of serum GOT, GPT and TB,	134
as previously described ¹⁸ .	135
	136
NOTE: Examinations of liver enzymes and TB level were carried out in the biochemical laboratory	137
of Soroka Medical Center. Blood samples were analyzed using a fluorescence method on a	138
chemistry analyzer (Table of Materials).	139
	140
3. Induction of acute liver injury in rats	141
	142
CAUTION: Exposure to high concentrations of CCl ₄ , including absorption through vapor or skin,	143
can have negative effects on the central nervous system and cause degeneration of the liver and	144
kidneys. Prolonged exposure can cause coma or death.	145
0.4.5	146
3.1. Prepare a 50% solution of CCl ₄ (Table of Materials) by mixing CCl ₄ with olive oil as a vehicle	147
in a 1:1 ratio.	148
NOTE The selection decided by a second consulting to IACHC a fideline for any absence of the last	149
NOTE: The solution should be prepared according to IACUC guidelines for non-pharmaceutical	150
grade compounds.	151
2.2. Induce hand to visit vin viva by CCL administration via an erogastric tube	152
3.2. Induce hepatotoxicity in vivo by CCl ₄ administration via an orogastric tube.	153 154
3.2.1. Insert a 16 G orogastric tube (3 inches deep) through the oral cavity of the rat.	154
3.2.1. Insert a 10 d orogastric tube (3 inches deep) through the oral cavity of the rat.	156
3.2.2. Expose the rat to different doses of CCl ₄ by injecting a syringe with one of the following	157
diluted solutions into the rat's stomach: 1 mL/kg (mild ALI), 2.5 mL/kg (moderate ALI), or 5 mL/kg	158
(severe ALI) of the 50% solution. For the sham-operated control group, expose the rat to 5 mL/kg	159
olive oil only.	160
	161
4. Determination of serum GOT, GPT, and TB levels after 24 h	162
	163
4.1. Anesthesia	164
	165
4.1.1. Prepare a continuous isoflurane administration system to induce anesthesia. Make sure	166
the vaporizer system is filled with isoflurane.	167
	168
4.1.2. Anesthetize the rats with 2% isoflurane. Confirm that the rat is fully anesthetized by	169
observing the movement and pedal reflex in response to external stimuli.	170
	171
4.2. Collect blood samples at 24 h from CCl ₄ exposure.	172
	173
4.3. Perform blood biochemical analysis including measurements of serum GOT, GPT and TB.	174
	175
5. Liver collection for histological examination	176

	177
5.1. Euthanize the rat by replacing the inspired gas mixture with 20% O ₂ /80% CO ₂ . Ensure that	178
CO ₂ is delivered at a predetermined rate in accordance with IACUC guidelines.	179
	180
5.2. Ensure death by checking for lack of heartbeat and confirm by a secondary method in	181
accordance with IACUC guidelines.	182
	183
5.3. Place the rat on a dissecting board with its dorsal surface facing down and abdomen facing	184
up. Shave the abdomen of the rat.	185
	186
5.4. With a scalpel, incise the full length of the ventrum skin from the anus to the chin. Separate	187
the skin. Incise the abdominal wall with a scalpel from the anus to the xyphoid cartilage, exposing	188
the abdominal viscera.	189
	190
5.5. Using scissors and forceps, isolate the liver by dissecting it from its ligaments and	191
attachments. Starting at the liver hilum, carefully perform a hepatectomy by releasing all the liver	192
lobes from attachments. Dissect and cut away all ligaments and blood vessels.	193
	194
5.6. Transfer the liver into a Petri dish. Fix the liver in a 4% buffered formaldehyde solution (Table	195
of Materials) for at least 24 h.	196
	197
6. Histological examination	198
	199
6.1. Sample preparation	200
	201
$6.1.1.$ After fixation, cut the sample into 5 μm thick slice series by microtome sectioning.	202
	203
6.1.2. Gently place the slices on glass slides with a soft brush, 1 slice per slide.	204
	205
6.1.3. Perform H&E staining as previously described ¹⁹ .	206
	207
6.2. Examine the slices under a microscope at 200x magnification using a 20 mm objective lens	208
(Table of Materials).	209
	210
NOTE: The liver sections should be graded by a specialized pathologist blinded to the treatment	211
protocol. A score of 0 indicates no liver abnormalities, 1–2 indicates mild liver injury, 3–4	212
indicates moderate liver injury, and 5–6 indicates severe liver injury ²⁰⁻²² .	213
	214
REPRESENTATIVE RESULTS:	215
The TB, GOT, and GPT levels significantly increased 24 h after inducing ALI (more at higher CCI ₄	216
doses) compared to sham-operated controls (p < 0.001) (Figure 1). The levels of TB, GOT, and	217
GPT at baseline were normal and were not significantly different than sham-operated controls.	218
At 24 h, all three interventional groups, 1 mL/kg CCl ₄ (1, 1–2), 2.5 mL/kg CCl ₄ (3, 3–4), and 5 mL/kg CCl ₄ (4, 4–5.75), had a significantly higher histological grading score than the sham-operated	219 220

control group (0, 0-0) (p < 0.05, data presented as median, 25–75% range). The H&E images of a sham-operated control (**Figure 2A**) and groups exposed to different CCl₄ doses (**Figure 2B–D**) show histopathological changes 24 h after CCl₄ exposure. Disruption of hepatocellular architecture by CCl₄ was demonstrated by a high grade of tissue injury with large fibrous septa deformation, extension of fibers, collagen accumulation, and pseudo lobe separation in liver sections (**Figure 2**).

FIGURE AND TABLE LEGENDS:

Figure 1: Serum TB (A), GOT (B), and GPT (C) levels in blood samples 24 h after exposure to different CCl₄ doses compared to sham-operated controls. Blue bar: control; red bar: 24 h after CCl₄ exposure. The significance of comparisons between CCl₄-exposed rats and unexposed rats are determined using the Mann–Whitney test. A p-value of <0.05 was considered significant.

Figure 2: Histopathological changes in liver tissue stained with H&E after 24 h CCl₄ intoxication in various doses. (A) sham-operated control, (B) 1 mL/kg CCl₄, (C) 2.5 mL/kg CCl₄, and (D) 5 mL/kg CCl₄. Scale bar = 50 μ m. The distribution of the histological outcomes was predicted by linear regression.

Table 1: Demonstration of the protocol timeline. The various groups of rats at different times include a sham-operated control group, mild ALI (exposure to 1 mL/kg CCl₄), moderate ALI (exposure to 2.5 mL/kg CCl₄), and severe ALI (exposure to 5 mL/kg CCl₄). At time 24 h, serum GOT, GPT and TB levels were measured, and histological examination was performed for all four groups.

DISCUSSION:

In this protocol, CCl₄ is used as a liver toxin to induce ALI in rats. ALI is characterized by loss of hepatic parenchyma and subsequent dysregulation of the liver's metabolic and synthetic functions. Drugs, viruses, toxins, autoimmune diseases, metabolic diseases, and vascular disorders all induce hepatocyte death, and the subsequent inflammatory response contributes to the pathogenesis of ALI.

The initial insult to the liver leads to cytokine production, chemokine release, and subsequent infiltration of inflammatory cells into the liver. Three of the commonly tested biomarkers for ALI evaluation are GPT, GOT and TB levels. GPT and GOT are enzymes measured by activity level while TB level measures liver function by serum concentration. When elevated, serum enzyme activity levels denote injury to hepatocytes or cholangiocytes²³. Rapid spectrophotometric method was first reported in the work of Arthur Karmen in 1955²⁴, which allowed for the widespread clinical application of serum enzyme measurement. Since then, GOT and GPT measurements have also been applied to detect hepatocyte injury. GPT is used more frequently, and simultaneous GPT testing usually reveals redundant results. The increase in activity levels of GOT and GPT between the release rates and the clearance rates from injured cells can be used to measure approximately the rate of injury to the cells. When the injured liver cells cause the liver to fail in its normal activities, such as processing and removing bilirubin as bile, this indicates that the ALI is more severe.

There are several steps in the protocol that are critical and merit careful consideration. Most protocols require serum biomarker testing before and after exposure to the investigative agent, as elevations in serum enzyme concentration levels are common. However, due to fluctuations in the timing of elevated ALT, several tests should be conducted periodically to detect any elevation. In this protocol, we chose to test GOT, GPT and TB levels at baseline and 24 h after exposure to the toxin. According to recent studies, the levels of these biomarkers correlated well with the severity of ALI during this time interval¹⁷. As shown in **Figure 1**, levels of blood GOT, GPT, and TB were elevated in all samples 24 h after inducing ALI. This indicates that the model has quantified outcomes in a very short time interval since exposure to CCl₄. One should take into account that in severe ALI the liver loses its ability to synthesize GOT and GPT. Therefore, in these cases these enzymes may lack their predictive value as demonstrated in the literature.

Histological findings of rats exposed to CCl₄ are characterized by ballooning of cells, centrilobular necrosis and the presence of Councilman bodies²⁵. In this model there was widespread damage shown to be proportional to the dose of CCl₄ administered.

This method of inducing ALI via orogastric CCl₄ exposure has numerous advantages. It is simple, inexpensive, and with minimum hazard risk. The protocol provides significant results in a very short time interval. The model is highly reproducible and can be commonly used to determine the efficacy of potential hepatoprotective strategies and assess markers of liver injury.

It is important to note that CCl_4 mainly affects the central zone of the liver, which does not match the massive necrosis typically seen in human liver failure. Moreover, CCl_4 is not completely metabolized in the liver, and some of the nonmetabolized CCl_4 can damage other organs, including lungs and kidneys¹⁶. In addition, due to different levels of cytochrome P450 development and efficacy, there is a large variation in sensitivity depending on species and age²⁶. Despite these limitations, the method of orogastric CCl_4 -induced ALI still serves as a valuable rodent model.

ACKNOWLEDGMENTS:

The authors gratefully acknowledge Bertha Delgado, Department of Pathology, Soroka Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, for her help in the laboratory as well as in the histology analysis.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:


1. Hoofnagle, J.H., Carithers, R.L., Shapiro, C., Ascher, N. Fulminant hepatic failure: Summary of a workshop. *Hepatology*. **21** (1), 240-252 (1995).


2. Rakela, J., Lange, S.M., Ludwig, J., Baldus, W.P. Fulminant hepatitis: Mayo clinic experience with 34 cases. *Mayo Clinic Proceedings*. **60** (5), 289-292 (1985).


3. Riordan, S.M., Williams, R. Treatment of hepatic encephalopathy. *New England Journal of Medicine*. **337**, 473-479 (1997).


- 4. Bernuau, J., Rueff, B., Benhamou, J.. Fulminant and subfulminant liver failure: Definitions and causes. *Seminars in Liver Disease*. **6** (2), 97-106 (1986).
- 5. Lidofsky, S.D. Liver transplantation for fulminant hepatic failure. *Gastroenterology Clinics of North America*. **22** (2), 257-69 (1993).
- 6. Auzinger, G., Wendon, J. Intensive care management of acute liver failure. *Current opinion in critical care*. **14** (2), 179-188 (2008).
- 7. Wu, Q. et al. Protection of regenerating liver after partial hepatectomy from carbon tetrachloride hepatotoxicity in rats: Roles of mitochondrial uncoupling protein 2 and ATP stores. *Digestive Diseases and Sciences.* **54** (9), 1918-1925 (2009).
- 8. Tuñón, M.J., Alvarez, M., Culebras, J.M., González-Gallego, J. An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure. *World Journal of Gastroenterologyl.* **15** (25), 3086-3098 (2009).
- 9. van de Kerkhove, M.P., Hoekstra, R., van Gulik, T.M., Chamuleau, R.A. Large animal models of fulminant hepatic failure in artificial and bioartificial liver support research. *Biomaterials*. **25** (9), 1613-25 (2004).
- 10. Butterworth, R.F. et al. Experimental models of hepatic encephalopathy: ISHEN guidelines. *Liver International.* **29** (6), 783-788 (2009).
- 11. Zhang, B., Gong, D., Mei, M. Protection of regenerating liver after partial hepatectomy from carbon tetrachloride hepatotoxicity in rats: Role of hepatic stimulator substance. *Journal of Gastroenterology and Hepatology.* **14** (10), 1010-1017 (1999).
- 12. Ugazio, G., Danni, O., Milillo, P., Burdino, E., Congiu, A.M. Mechanism of protection against carbon tetrachloride toxicity. I. prevention of lethal effects by partial surgical hepatectomy. *Drug and Chemical Toxicology*. **5** (2), 115-24 (1982).
- 13. Taniguchi, M., Takeuchi, T., Nakatsuka, R., Watanabe, T., Sato, K. Molecular process in acute liver injury and regeneration induced by carbon tetrachloride. *Life Science*. **75** (13), 1539-1549 (2004).
- 14. Gordis, E. Lipid metabolites of carbon tetrachloride. *Journal of Clinical Investigation*. **48** (1), 203-209 (1969).
- 15. Albrecht, J. Cerebral RNA synthesis in experimental hepatogenic encephalopathy. *Journal of Neuroscience Research*. **6** (4), 553-558 (1981).
- 16. Terblanche, J., Hickman, R. Animal models of fulminant hepatic failure. *Digestive Diseases and Sciences.* **36** (6), 770-774 (1991).
- 17. Gruenbaum, B.F., et al. Cell-free DNA as a potential marker to predict carbon tetrachloride-induced acute liver injury in rats. *Hepatology International*. **7** (2), 721-727 (2013).
- 18. Juricek, J., et al. Analytical evaluation of the clinical chemistry analyzer Olympus AU2700 plus. *Biochemia Medica.* **20** (3), 334-340 (2010).
- 19. Feldman, A.T., Wolfe, D. Tissue processing and hematoxylin and eosin staining. *Methods in Molecular Biology.* **1180**, 31-43 (2014).
- 20. Wang, T., et al. Protective effects of dehydrocavidine on carbon tetrachloride-induced acute hepatotoxicity in rats. *Journal of Ethnopharmacology.* **117** (2), 300-308 (2008).

21. Ye, X., et al. Hepatoprotective effects of coptidis rhizoma aqueous extract on carbon	350
tetrachloride-induced acute liver hepatotoxicity in rats. Journal of Ethnopharmacology. 124 (1),	351
130-136 (2009).	352
22. Wills, P.J., Asha, V.V. Protective effect of lygodium flexuosum (L.) sw. extract against carbon	353
tetrachloride-induced acute liver injury in rats. Journal of Ethnopharmacology. 108 (3), 320-326	354
(2006).	355
23. Senior, J.R. Monitoring for hepatotoxicity: What is the predictive value of liver "function"	356
tests? Clinical Pharmacology & Therapeutics. 85 (3), 331-334 (2009).	357
24. Karmen, A. A note on the spectrometric assay of glutamic-oxalacetic transaminase in human	358
blood serum. Journal of Clinical Investigation. 34 (1), 131-133 (1955).	359
25. Hubner, G. Ultrastructural liver damage caused by direct action of carbon tetrachloride in	360
vivo and in vitro. Virchows Archiv fur Pathologische Anatomie und Physiologie und fur Klinische	361
Medizin. 339 (3), 187-197 (1965).	362
26. Newsome, P.N., Plevris, J.N., Nelson, L.J., Hayes, P.C. Animal models of fulminant hepatic	363
failure: A critical evaluation. Liver Transplantation. 6 (1), 21-31 (2000).	364










Groups	0 hours	24 hours
Sham (15 rats)	GOT, GPT, TB baseline level	GOT, GPT, TB level
Mild ALI (15 rats)		
Moderate ALI (15 rats)	CCl ₄ exposure for ALI groups and olive oil for sham group	Histological examination
Severe ALI (18 rats)		

Name of Material/Equipment	Company	Catalog Number
22 G catheter BD Neoflon TM	Becton Dickinson Infusion Therapy AB	
4% buffered formaldehyde solution	Sigma - Aldrich lab materials technologies Becton Dickinson and	
BD Microtainer SST TM Tubes	Company	
Carbone tetrachloride Isofluran, USP 100% Olympus AU2700 Chemistry-	Sigma - Aldrich lab materials technologies Piramamal Critical Care, Inc	
Immuno Analyzer	Olympus (MN, USA)	
Olympus BX 40 microscope RAT Feeding Needles	Olympus ORCHID SCIENTIFICS Shandong Zibo	
SYRINGE SET 1 and 2 ml MEDI - PLUS	Shanchuan Medical Instruments Co., Ltd	



Attn: Xiaoyan Cao, Ph.D.

Review Editor

Journal of Visualized Experiments (JoVE)

JoVE60695R3

Title: Inducing acute liver injury in rats via carbon tetrachloride (CCl4) exposure through an orogastric tube

Dear Dr. Cao,

Please find attached a revised version of the manuscript JoVE60695R3, with changes highlighted in yellow. Below is a point-by point response to each of the reviewer's comments. We very much hope that this revised manuscript is now suitable for publication in the JoVE.

We thank you and the reviewers for your consideration.

Best regards,

Matthew Boyko, PhD

Editorial comments:

Changes to be made regarding the manuscript:

1. Please note that the editor has formatted the manuscript to match the journal's style. Please retain the same. The updated manuscript is attached and please use this version to incorporate the changes that are requested.

Thank you. This has been done.

2. Please address specific comments marked in the attached manuscript (results and figure legends).

All of these comments have been addressed and incorporated into the manuscript.

3. Figure 1: Please change "ml" to "mL" and include a space between numbers and their units (1 mL/kg, 2.5 mL/kg, 5 mL/kg). Please change "CCL4" to "CCl4 (4 should be subscript)".

Done.

4. Please upload Table 1 as an .xlsx file.

Done.

Changes to be made regarding the video:

1. @5:00: Please replace with the updated Figure 1.

Done.

2. Please upload your revised video here: https://www.dropbox.com/request/62bU8dUAzhpQLv1DaYSZ?oref=e

Done.